Vericel Corporation (VCEL) is a publicly traded Healthcare sector company. As of May 21, 2026, VCEL trades at $35.55 with a market cap of $1.78B and a P/E ratio of 106.46. VCEL moved +2.65% today. Year to date, VCEL is -4.53%; over the trailing twelve months it is -18.66%. Its 52-week range spans $28.95 to $63.00. Analyst consensus is strong buy with an average price target of $61.25. Rallies surfaces VCEL's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Vericel’s Q1 Revenue Jumps 30% to $68.4M, Guidance Raised to $336M: Vericel’s first-quarter revenue climbed 30% year-over-year to $68.4 million, driven by 22% MACI growth to $56.4 million and a 91% surge in burn care sales to $12.0 million. The company raised its full-year 2026 revenue outlook by $10 million to a range of $326–$336 million.
| Metric | Value |
|---|---|
| Price | $35.55 |
| Market Cap | $1.78B |
| P/E Ratio | 106.46 |
| EPS | $0.33 |
| Dividend Yield | 0.00% |
| 52-Week High | $63.00 |
| 52-Week Low | $28.95 |
| Volume | 83 |
| Avg Volume | 0 |
| Revenue (TTM) | $276.26M |
| Net Income | $16.52M |
| Gross Margin | 74.42% |
6 analysts cover VCEL: 0 strong buy, 5 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $61.25.